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Abstract
Background: In the western world, heart failure (HF) is one of the most important causes of cardiovascular
mortality. Supplement with n-3 polyunsaturated fatty acids (PUFA) has been shown to improve cardiac function in
HF and to decrease mortality after myocardial infarction (MI). The molecular structure and composition of n-3 PUFA
varies between different marine sources and this may be of importance for their biological effects. Krill oil, unlike
fish oil supplements, contains the major part of the n-3 PUFA in the form of phospholipids. This study investigated
effects of krill oil on cardiac remodeling after experimental MI. Rats were randomised to pre-treatment with krill oil
or control feed 14 days before induction of MI. Seven days post-MI, the rats were examined with echocardiography
and rats in the control group were further randomised to continued control feed or krill oil feed for 7 weeks
before re-examination with echocardiography and euthanization.
Results: The echocardiographic evaluation showed significant attenuation of LV dilatation in the group pretreated
with krill oil compared to controls. Attenuated heart weight, lung weight, and levels of mRNA encoding classical
markers of LV stress, matrix remodeling and inflammation reflected these findings. The total composition of fatty
acids were examined in the left ventricular (LV) tissue and all rats treated with krill oil showed a significantly higher
proportion of n-3 PUFA in the LV tissue, although no difference was seen between the two krill oil groups.
Conclusions: Supplement with krill oil leads to a proportional increase of n-3 PUFA in myocardial tissue and
supplement given before induction of MI attenuates LV remodeling.
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Background
In the western world, heart failure (HF) is one of the
most important causes of cardiovascular mortality and
myocardial infarction (MI) constitutes a major etiologic
factor precipitating HF [1]. The molecular and cellular
pathological processes that ultimately lead to HF are
collectively referred to as cardiac remodeling and are
characterized by cardiomyocyte hypertrophy, ventricular
dilatation, and development of myocardial fibrosis [2].
Metabolic alterations also occur during development of
HF with the hallmark change being a shift from myocar-
dial oxidation of fatty acids (FA) to utilization of glucose
as the main source of energy generation. Since metabolism
of glucose requires less oxygen, this shift may be beneficial
for the heart [3,4]. However, plasma FA may still consti-
tute an important source of energy in HF, and it has been
suggested that cardiac accumulation of lipids in HF can
result in lipotoxicity and therefore contributes to the
detoriation of cardiac function [4]. However, these issues
are far from clear and even though some FA may be con-
sidered harmful, others, like n-3 polyunsaturated FA
(PUFA), have been shown to decrease mortality after MI
and in HF [5-7]. It has also been suggested that the com-
position of FA bound to the plasma membrane phospholi-
pids may be of importance to myocardial function. In line
with this notion, it has been shown that the pro-inflamma-
tory membrane component arachidonic acid (AA) can be
replaced with eicosapentaenoic acid (EPA) or docosahex-
aenoic acid (DHA) with an increased dietary intake of
these n-3 PUFA [8].
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Krill (Euphausia superba) is a small Antarctic crustacean
and its extracted oil contains a high proportion of n-3
PUFA bound to phospholipids. This molecular makeup is
different from traditional fish oils, where the n-3 PUFA
are mainly bound to triglycerides or ethyl esters [9]. This
difference may be important as the molecular form of n-3
PUFA has been suggested relevant for their biological
effects [10]. Furthermore, phospholipids themselves have
been shown to have beneficial effects on lipid metabolism
[11]. These properties could suggest a beneficial effect of
krill oil during MI and post-MI remodeling. To further
elucidate this issue, we investigated the effects of krill oil
on cardiac remodeling and function in rats after MI.
Results
Effect of krill oil on cardiac structure and function
There were no significant differences in tibia length (TL)
and increase of body weight (BW) after 8 weeks between
the MI groups. However, the heart weight-to-body weight
and the lung weight-to-body weight ratios was significantly
smaller in the MI-krill oil pretreated (PT) group compared
to the MI-control and MI-krill oil non-pretreated (nPT)
groups at 8 weeks (Table 1).
As expected, there was a significant increase in left ven-
tricular (LV) end-diastolic diameter (LVEDD) in the MI-
control group compared to the sham group (Figure 1).
More importantly, the MI-krill oil PT group showed sig-
nificantly less LV dilatation during the treatment period
compared to both the MI-control and the MI-krill oil nPT
group. An increase in LVEDD was seen in the MI-krill oil
nPT group compared to the MI-control group. There
were no differences in the change of posterior wall
thickness (PWT) or fractional shortening (FS) between the
different MI groups. However, the change in relative wall
thickness (RWT) was significantly lower in the MI-krill oil
PT group, compared to the MI-krill oil nPT group.
Effects of krill oil on plasma lipids
Several significant alterations in plasma lipid levels were
observed (Table 2). There were no significant differences
in plasma lipids between the two krill oil groups, except
that high-density lipoprotein (HDL)-cholesterol were
lower in the MI-krill oil PT group compared to the MI-
krill oil nPT group. However, when comparing the two
krill oil groups to the MI-control group, the krill oil
treated groups showed significantly reduced levels of
total-, free- and low-density lipoprotein (LDL)-choles-
terol as well as phospholipids and free FA (FFA) in
plasma. Furthermore, levels of triglycerides were signifi-
cantly higher in the MI-krill oil PT group than in the
MI-control group.
Effects of krill oil on myocardial FA composition
There were no regional myocardial differences (non-
infarcted vs border zone tissue) in the composition of
FA in any of the groups (data not shown). As a conse-
quence, the more elaborate analyses were performed
only on non-infarcted tissue. Whereas the total amount
of FA were unaffected upon induction of MI, the rela-
tive level of saturated FA (SFA) and n-3 PUFA were
slightly elevated in the MI-control group when com-
pared to the sham group. However, compared to the
MI-control group, treatment with krill oil resulted in a
higher myocardial proportion of n-3 PUFA and a lower
Table 1 Effect of krill oil on heart and lung weights and cardiac structure and function at baseline (before MI) and 1
and 8 weeks after induction of MI
Control feed Krill oil feed
Sham MI MI-nPT MI-PT
Baseline: BW (g) 273 ± 3 261 ± 3# 271 ± 2 270 ± 2*
1 week: LVEDD (mm) 5.0 ± 0.2 8.1 ± 0.2### 7.9 ± 0.2 8.3 ± 0.2
PWT (mm) 2.4 ± 0.1 2.2 ± 0.1# 2.3 ± 0.1 2.2 ± 0.1
FS (%) 68 ± 2 21 ± 1### 22 ± 1 21 ± 1
RWT 2.5 ± 0.1 2.2 ± 0.1### 2.3 ± 0.2 2.2 ± 0.1
8 weeks: BW (g) 427 ± 7 397 ± 9# 427 ± 8* 425 ± 6*
TL (mm) 38 ± 0.2 38 ± 0.4 38 ± 0.2 38 ± 0.3
HW/BW (mg/g) 2.7 ± 0.2 3.7 ± 0.2## 3.6 ± 0.2 3.1 ± 0.1*†
LW/BW (mg/g) 3.2 ± 0.1 6.2 ± 0.5## 6.3 ± 0.7 4.3 ± 0.5**†
LVEDD (mm) 6.0 ± 0.2 10.5 ± 0.3### 11.1 ± 0.3 9.8 ± 0.3††
PWT (mm) 3.1 ± 0.2 2.3 ± 0.1## 2.3 ± 0.1 2.4 ± 0.1
FS (%) 69 ± 3 18 ± 1### 16 ± 1 18 ± 1
RWT 3.1 ± 0.2 2.3 ± 0.1### 2.3 ± 0.1 2.4 ± 0.1
MI, myocardial infarction; nPT, non-pretreated; PT, pretreated; BW, body weight; TL, tibia length; HW, hearth weight; LW, lung weight; LEVDD, left ventricular
diastolic diameter; PWT, posterior wall thickness; RWT, relative wall thickness; FS, fractional shortning. Values are mean ± SEM. #P ≤ 0.05 vs sham, ##P ≤ 0.01 vs
sham, ###P ≤ 0.001 vs sham, *P ≤ 0.05 vs MI-control, **P ≤ 0.01 vs MI-control, ***P ≤ 0.001 vs MI-control, †P ≤ 0.05 vs MI-nPT, ††P ≤ 0.01 vs MI-nPT, †††P ≤ 0.001
sv MI-nPT.
Fosshaug et al. Lipids in Health and Disease 2011, 10:245
http://www.lipidworld.com/content/10/1/245
Page 2 of 9
Figure 1 Effect of krill oil on change in myocardial function and structure post-MI. MI, myocardial infarction; nPT, non-pretreated; PT,
pretreated; BW, body weight; LVEDD, left ventricular diastolic diameter; PWT, posterior wall thickness; RWT, relative wall thickness; FS, fractional
shortning.#P ≤ 0.05 vs sham *P ≤ 0.05 vs MI-control. †P ≤ 0.05 vs MI-nPT.
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relative level of n-6 PUFA, resulting in an increased n-3/
n-6 PUFA ratio (Table 3). EPA (20:5 n-3) and DHA
(22:6 n-3), both documented to be beneficial after MI
and in HF in humans, were proportionally increased in
the krill oil-treated groups. There were no differences in
n-3 PUFA, n-6 PUFA, EPA, or DHA between the MI-
krill oil PT and MI-krill oil nPT groups.
Alterations of genes involved in cardiac remodeling
Significantly attenuated levels of mRNA encoding classi-
cal markers of LV stress and matrix remodeling were
observed in the MI-krill oil PT rats compared to the
MI-control rats (Table 4). The same observation was
not seen in the nPT rats. Furthermore, the mRNA levels
of classical inflammatory mediators, like interleukin
(IL)-6, were significantly lower in the MI-krill oil PT
group compared to both the MI-control and MI-krill oil
nPT groups.
Discussion
In the present study, we show that treatment with krill
oil prior to induction of MI attenuates ventricular dila-
tation and hypertrophy. These findings were further
reflected by attenuated increase in lung weight, heart
weight, and altered expression of various genes encoding
peptides known as markers and mediators of myocardial
remodeling. However, when treatment with krill oil was
introduced 7 days after MI, increased ventricular dilata-
tion was seen.
Since the beneficial effects of krill oil were dependent
on initiation of treatment before induction of MI, our
data indicate that krill oil may have a favorable influence
on the initial remodeling process after MI. This hypoth-
esis is supported by previous experimental studies
demonstrating that n-3 PUFA given prior to aortic
banding protects against ventricular remodeling and
dysfunction in rats [8,12-15]. In the GISSI-HF trial,
Table 2 Effect of krill oil on plasma lipid concentrations 8 weeks after MI
Control feed Krill oil feed
Sham MI MI-nPT MI-PT
mmol/L
Total cholesterol 2.09 ± 0,14 1.93 ± 0.08 1.73 ± 0.10* 1.59 ± 0.06**
HDL cholesterol 1.31 ± 0.07 1.33 ± 0.06 1.22 ± 0.06 1.05 ± 0.04***†
LDL cholesterol 0.24 ± 0.04 0.25 ± 0.02 0.20 ± 0.02* 0.16 ± 0.02**
Free cholesterol 0.56 ± 0.04 0.49 ± 0.02# 0.42 ± 0.02* 0.40 ± 0.01**
Triglycerides 1.67 ± 0.24 1.12 ± 0.17 1.53 ± 0.14* 1.59 ± 0.11**
Phospholipids 2.19 ± 0.12 1.91 ± 0.06# 1.75 ± 0.07 1.73 ± 0.05*
FFA 0.15 ± 0.04 0.34 ± 0.05# 0.12 ± 0.03** 0.11 ± 0.02***
Glucose 11.8 ± 0.47 11.6 ± 0.39 11.1 ± 0.37 10.8 ± 0.41
MI, myocardial infarction; nPT, non-pretreated; PT, pretreated; HDL, high density lipoprotein; LDL, low density lipoprotein; FFA, free fatty acids. Values are mean ±
SEM. #P ≤ 0.05 vs sham, *P ≤ 0.05 vs MI-control, **P ≤ 0.01 vsMI-control, ***P ≤ 0.001 vs MI-control, †P ≤ 0.05 vs MI-nPT.
Table 3 Effect of krill oil on myocardial fatty acid composition 8 weeks after MI
Control feed Krill oil feed
Sham MI MI-nPT MI-PT
μg FA/g tissue
Total FA 25240 ± 1342 24911 ± 3701 22585 ± 1912* 23935 ± 1205†
wt.% of total FA
Palmitic acid 9.41 ± 0.25 11.07 ± 0.38## 11.72 ± 0.11*** 11.78 ± 0.11***
EPA 0.18 ± 0.01 0.18 ± 0.01 1.58 ± 0.07*** 1.75 ± 0.06***
DPA 2.04 ± 0.06 2.40 ± 0.09# 3.62 ± 0.08*** 3.61 ± 0.08***
DHA 8.98 ± 0.41 10.6 ± 0.44# 16.06 ± 0.03*** 15.77 ± 0.29***
AA 22.9 ± 0.42 23.77 ± 0.7# 17.16 ± 0.32*** 14.37 ± 0.29***†††
SFA 30.4 ± 0.25 31.8 ± 0.16### 32.0 ± 0.17 31.3 ± 0.15†
MUFA 8.03 ± 0.33 8.8 ± 0.77 8.36 ± 0.22 8.8 ± 0.18
PUFA n-3 11.62 ± 0.44 13.6 ± 0.44## 21.59 ± 0.27*** 21.5 ± 0.31***
PUFA n-6 49.72 ± 0.59 45.6 ± 0.58### 37.89 ± 0.30*** 38.2 ± 0.38***
PUFA n-3/n-6 0.24 ± 0.01 0.30 ± 0.01### 0.57 ± 0.01*** 0.6 ± 0.01***
MI, myocardial infarction; nPT, non-pretreated; PT, pretreated; wt.%, weight percent; FA, fatty acids; EPA, eicosapentaenoic acid; DPA, docosapentaenoic acid;
DHA, docosahexaenoic acid; AA, arachidonic acid; SFA, saturated FA; MUFA, monounsaturated FA; PUFA, polyunsaturated FA. Values are mean ± SEM. #P ≤ 0.05
vs sham, ##P ≤ 0.01 vs sham, ###P ≤ 0.001 vs sham, *P ≤ 0.05 vs MI-control, ***P ≤ 0.001 vs MI-control, †P ≤ 0.05 vs MI-nPT, †††P ≤ 0.001 vs MI-nPT.
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significant reductions in overall mortality and hospital
admissions in patients with chronic HF were seen in
patients receiving n-3 PUFA in the form of ethyl esters
[6]. In a sub-study of GISSI-HF, the effects of n-3 PUFA
on LV structure and function were investigated, and a
small but significant effect on LV ejection fraction was
observed [16]. In addition, a small study in patients with
non-ischemic cardiomyopathy demonstrated increased
LV ejection fraction after 12 months of supplementation
with 2 g of n-3 PUFA [17]. However, no effects on LV
structure were found, which support our hypothesis that
krill oil may have beneficial effects on the initial cardiac
remodeling process after MI rather than on the remo-
deling process in the more chronic phases after MI.
The rats pretreated with krill oil showed attenuated
expression of several mRNA known to be involved in the
cardiac remodeling process; tissue inhibitor of matrix
metalloproteinase (TIMP), atrial natriuretic peptide
(ANP), and IL-6. Several studies have shown that the bal-
ance of matrix metalloproteinase (MMP) and their endo-
genous inhibitors TIMP is an important regulator of
ventricular dimensions as they regulate structure and
function of the extracellular matrix (ECM) [18]. Myocar-
dial ANP levels have been observed to increase in response
to hemodynamic overload [19]. Also, elevated levels of
inflammatory cytokines, like IL-6, have been observed in
several studies on HF and cardiac remodeling [20]. In con-
sequence of the assumed involvement of TIMP, ANP, and
IL-6 in the regulation of the ECM structure and function,
lower expression of these mRNA levels in the myocardial
tissue could potentially be related to the echocardio-
graphic finding of less LV dilatation in the rats pretreated
with krill oil.
The beneficial effect of pretreatment with krill oil on
post-infarction cardiac remodeling may also be a result
of a favorable effect on MI size. Previous experimental
studies have observed that n-3 PUFA induces significant
myocardial resistance to ischemia-reperfusion injury and
thereby significant smaller myocardial infarct size in
rodents [21,22]. We therefore hypothesize that pretreat-
ment with krill oil, in addition to possible effects on early
cardiac remodeling, may also lead to smaller MI with less
LV dilatation and hypertrophy. However, in the present
study we have no data on MI size, and this hypothesis
will have to be further explored in forthcoming studies.
The potential beneficial effects of krill oil on post-MI
remodeling could have several explanations. First, as
shown in our study, dietary supplement with n-3 PUFA
leads to slightly reduced myocardial SFA levels. Substitut-
ing PUFA for SFA may be associated with lower risk of
coronary heart disease and studies on isolated myocardial
cells have shown that the SFA palmitic acid induces cardi-
omyocyte apoptosis under certain conditions [23,24]. Sec-
ond, krill oil supplementation induced an increase in
myocardial levels of EPA and DHA, which have been
shown to be incorporated into cell membranes in both
healthy and failing hearts [14,25]. This may lead to an
increased production of anti-inflammatory or resolving
mediators including resolvins of the E series. In contrast
to n-3 PUFA, n-6 PUFA may lead to enhanced generation
of inflammatory mediators including prostaglandin-E2 and
lipoxins. As a consequence, a relative decrease in n-6
PUFA during krill oil supplementation may further
enhance the anti-inflammatory properties of krill oil [8].
Finally, incorporation of n-3 PUFA into mitochondrial
membranes under conditions of myocardial stress has also
been hypothesized to be beneficial as it may help maintain
myocardial oxidative function [26].
Even though this study was not designed as to compare
the effects of fish oil to that of krill oil, other studies allows
hypothesizing that the molecular form of the supplemen-
ted n-3 PUFA is of importance to their various effects
[10]. It was recently demonstrated that the incorporation
of EPA and DHA into myocardial phospholipids was
higher when delivered in the form of krill oil/n-3 phospho-
lipids, compared to n-3 bound in the form of triglycerides
(fish oil) [27]. Two recent studies compared the absorption
of DHA and EPA from triglycerides versus phospholipid
n-3 PUFA sources and they showed that supplementation
with krill oil gave a dose-equivalent higher plasma concen-
tration of EPA and DHA in women and men compared to
fish oil [28,29].
Conclusions
In conclusion, although relatively few rats were studied,
our findings may suggest that treatment with krill oil
before MI leads to attenuated LV dilatation and hyper-
trophy in rats. However, future studies are needed to
establish whether these beneficial effects are
Table 4 Alterations on genes involved in cardiac
remodeling 8 weeks after MI
Control feed Krill oil feed
Sham MI MI-nPT MI-PT
Relative units
ANP 0.17 ± 0.05 2.08 ± 0.35### 2.48 ± 0.36 1.21 ± 0.19*††
MMP-2 0.59 ± 0.13 2.44 ± 0.65# 1.88 ± 0.39 2.41 ± 0.53
MMP-9 0.07 ± 0.02 0.35 ± 0.20## 1.28 ± 0.69 1.68 ± 1.30
TIMP 0.74 ± 0.05 1.71 ± 0.18# 1.60 ± 0.24 1.05 ± 0.14*†
CTGF 0.28 ± 0.01 0.94 ± 0.01 0.87 ± 0.15 1.27 ± 0.19
TGF-b 0.95 ± 0.14 1.83 ± 0.22# 1.90 ± 0.20 1.37 ± 0.11†
TNF-a 1.39 ± 0.30 0.89 ± 0.20 2.24 ± 0.33** 0.99 ± 0.14††
IL-1b 0.89 ± 0.15 0.80 ± 0.10 1.11 ± 0.14 0.66 ± 0.07††
IL-6 0.88 ± 0.38 6.91 ± 2.38## 4.37 ± 0.83 1.92 ± 0.30*†
MCP-1 1.20 ± 0.43 2.43 ± 0.53 3.00 ± 0.54 1.19 ± 0.10††
Values are mean ± SEM. #P ≤ 0.05 vs sham, ##P ≤ 0.01 vs sham, ###P ≤ 0.001
vs sham, *P ≤ 0.05 vs MI-control **P ≤ 0.01 vs MI-control, †P ≤ 0.05 vs MI-nPT,
††P ≤ 0.01 vs MI-nPT.
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consequences of attenuated cardiac remodeling or
reduction of MI sizes. Also, the molecular effects of krill
oil on the heart are not yet clear and need to be exam-
ined further.
Methods
Rat model of MI and treatment protocol
One week prior to induction of MI, male Wistar rats (n =
173) were randomized in to two groups; 1) Pretreatment
(PT) with Superba™ krill oil (Aker BioMarine ASA, Oslo,
Norway) in the feed (n = 45), and 2) control feed (n =
128) (Figure 2). The rats underwent induction of MI by
left coronary artery ligation as previously described [30]. A
group of rats on control feed (n = 8) were sham-operated
for comparison. Surviving rats (n = 97) were evaluated by
transthoracic echocardiography at 7 days post-MI and
only rats with transmural infarctions were included in the
study (n = 53). The MI-rats pretreated with krill oil (n =
18) were then continued on the same diet and rats on con-
trol feed were further randomized to: 1) Treatment with
krill oil (n = 17) and 2) control feed (n = 14). Treatment
was continued for 7 weeks before reevaluation with trans-
thoracic echocardiography and harvesting of the organs.
Mortality was low during the treatment period: MI-krill
oil PT group, 1 rat; MI-krill oil nPT group, 4 rats; MI-krill
oil group, 0 rats; Sham group, 0 rats. The amount of EPA
+DHA in 100 g of feed was 0.47 g, which is equivalent to
0.75% of the energy in the rat diet which corresponds to
1.67 g EPA+DHA/day in a 8.4-MJ/day diet in humans
(Table 5). The “Principle of laboratory animal care” (NIH
publication No. 86-23, revised 1985) was followed as well
as Norwegian national laws regarding animal care.
Wistar rats MI 
MI 
Sham 
operation 
Krill oil 
Control 
Control 
Krill oil 
Krill oil 
Control 
Control 
Control 
Surgery Echo- 
cardiography 
Echo- 
cardiography
14 days 7 days 7 weeks 
E 
u 
t 
h 
a 
n 
a 
s 
i 
a 
Figure 2 Experimental rat model and treatment protocol. Rats with transmural MIs were randomized in to three groups: 1) Krill oil prior to
and after MI, 2) a control diet prior to and after induction of MI, or 3) a control diet prior to and 7 days after induction of MI, thereafter krill oil.
Surviving rats were killed 8 weeks after the surgical procedure. In addition, a sham-operated group of rats were included on a normal feed for
the entire length of the study.
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Echocardiography
Echocardiography was performed prior to randomization
7 days after the surgical procedure and after 7 weeks of
treatment (8 weeks post-surgery). The rats were sedated
with 0.3 ml/100 g body wt Hypnorm®-Dormicum® [2.5%
Hypnorm® (VetaPharma; fentanyl 0.315 mg/ml + fluani-
sone 10 mg/ml) + 25% Dormicum® (Roche; midazolam 5
mg/ml) in water]. Transthoracic echocardiography was
performed with a Vivid 7 scanner (GE) and a 14-MHz
transducer. Two-dimensional-directed M-Mode echocar-
diography was obtained in the parasternal short-axis view
at the level of the papillary muscles. The various echocar-
diographic parameters were calculated as follows: FS =
LVEDD-LV end-systolic diameter (LVESD)/LVEDD)] ×
100; RWT = PWT in diastole/LV internal radius (radius =
0.5 × LVEDD).
Blood and tissue sampling
At the end of the study, blood was drawn from the
abdominal aorta into EDTA-containing tubes and centri-
fuged within 20 min at 4°C (2000g for 20 min), plasma
was aspirated, and then stored at -80°C until further ana-
lyses. The heart and lungs were weighed, and the tibia
lengths were measured. The LV (septum and free wall)
was separated from the rest of the heart and further sec-
tioned into infarcted area, non-infarcted area, and the bor-
der zone between these two regions (approximately width
of 2 mm). The tissue was immediately frozen in liquid
nitrogen and stored at -80°C until further analysis.
Isolation of total RNA, reverse transcription and real-time
PCR analysis
Total RNA was extracted with acid-buffered phenol
(Trizol®, Invitrogen, San Diego, CA), DNase treated,
and further purified using RNeasy mini columns (Qia-
gen, Hilden, Germany). cDNA was prepared using the
High-Capacity cDNA Archive Kit (Applied Biosystems,
Foster City, CA) according to the manufacturer’s
instruction. Primer sequences were designed using the
Primer Express software version 3.0 (Applied Biosys-
tems, Foster City, CA), sequence information can be
provided on request. Quantitative real-time PCR analysis
was performed using an ABI Prism 7300 sequence
detector (Applied Biosystems) and SYBR Green assays
(qPCR Master Mix for SYBR Green I, Eurogentec, Sera-
ing, Belgium). The ribosomal RNA P0 was used as an
internal standard for normalization of target mRNA.
Lipid analysis
Plasma lipids were measured on the Hitachi 917 system
(Roche Diagnostics GmbH, Mannheim, Germany) using
the following kits: total cholesterol (Bayer, Tarrytown,
NY), free cholesterol (Wako Chemicals, Dalton, OH),
HDL-cholesterol (HDL-C Plus, Roche Diagnostics
GmbH), LDL-cholesterol (LDL-C Plus, Roche Diagnos-
tics GmbH), triglycerides (Bayer), and phospholipids
(PAP 150, bioMérieux, Lyon, France).
Free FA and total levels and composition of FA
Plasma free FA (FFA) were measured on the Hitachi 917
system (Roche Diagnostics) using a commercially avail-
able FFA kit (NEFA [non-esterified FA] C, Wako Che-
micals, Neuss, Germany). Measurement of total levels
and composition of FA was performed after extracting
lipids from the myocardial tissue using a mixture of
chloroform and methanol. The extracts were transesteri-
fied using BF3-methanol. To remove neutral sterols and
non-saponifiable material, extracts of fatty acyl methyl
Table 5 Fatty acid composition (grams pr 100 g diet) of the feeds as determined from reference values for the soy
and krill oils mixed into the feeds
Fatty acid Control diet Krill oil diet
g/100 g diet
Palmitic acid 0.68 0.68
Stearic acid 0.29 0.20
Oleic acid 1.46 1.12
Linoleic acid 3.27 2.12
Alpha-linolenic acid 0.44 0.30
EPA 0 0.30
DHA 0 0.17
Arachidonic acid 0.01 0.01
SFA 1.02 1.00
MUFA 1.48 1.18
PUFA n-3 0.44 0.83
PUFA n-6 3.27 2.12
PUFA n-3/n-6 0.13 0.39
FA, fatty acids; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; SFA, saturated FA; MUFA, monounsaturated FA; PUFA, polyunsaturated FA.
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esters were heated in 0.5 M KOH in ethanol-water solu-
tion (9:1). Recovered FA were re-esterified using BF3-
methanol. The methyl esters were quantified by gas
chromatography as previously described [31].
Statistical analysis
All data are presented as mean ± SEM. For comparisons
of two groups, the Mann-Whitney U test was used. For
comparison of over 3 groups, ANOVA with the Krus-
kal-Wallis test was used. If the Kruskal-Wallis revealed
significant differences, subsequent analyses of individual
means were performed with Mann-Whitney U test. A
value of P < 0.05 was considered statistically significant.
SPSS 18.0 was used for all analyses.
Abbreviations
AA: arachidonic acid; ANP: atrial natriuretic peptide; BW: body weight; CTGF:
connective tissue growth factor; DPA: docosapentaenoic acid; ECM:
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HW: heart weight; LV: left ventricular; LVEDD: LV end-diastolic diameter;
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